Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Clinical stages showed a progressively increased prevalence of Aβ-positivity and higher entorhinal tau PET pathology from cognitively normal (CN) to SOCD, MCI, and dementia in both tracers. MBI and SCD transitional groups showed no increased Aβ or tau pathology compared to CN (Figure 2). For this reason, only SOCD was considered part of stage 2 for following analyses. All tested biological staging strategies showed moderate agreement (0.34-0.59) with clinical stages using either tracers. The distribution of biological across clinical stages were similar for FTP and MK, with MK-6240 showing lower PPV values in earlier stages than FTP (Table 1). Our results support that AA-2024 biological and clinical stages show similar clinical-biological concordance using either Flortaucipir or MK-6240, although this can vary based on methods tested in the study. The MBI and SCD clinical subgroups showed no difference of pathological burden to clinical stage 1, while SOCD transitional stage showed higher burden compared to stage 1.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 446 participants. This study compared two tau PET tracers for staging Alzheimer's disease and found moderate agreement between biological and clinical staging with either tracer. It is a diagnostic comparison study and does not test any treatment, cure, or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Madeiros, M. S., Ferreira, P. C., Bellaver, B., Ruppert, E. P., Zalzale, H., Soares, C., et al. (2025). Diagnostic performance of MK and Flortaucipir tau PET for the biological staging of Alzheimer disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70857_107236

Vancouver

Madeiros MS, Ferreira PC, Bellaver B, Ruppert EP, Zalzale H, Soares C, et al. Diagnostic performance of MK and Flortaucipir tau PET for the biological staging of Alzheimer disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70857_107236. PMID: 41452137.

BibTeX

@article{madeiros2025-41452137,
  author  = {Madeiros, Marina Scop and Ferreira, Pâmela C.L. and Bellaver, Bruna and Ruppert, Emma Patrice and Zalzale, Hussein and Soares, Carolina and Bauer‐Negrini, Guilherme and Povala, Guilherme and others},
  title   = {{Diagnostic performance of MK and Flortaucipir tau PET for the biological staging of Alzheimer disease}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70857_107236},
  pmid    = {41452137},
  url     = {https://doi.org/10.1002/alz70857_107236}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study compared two tau PET tracers for staging Alzheimer's disease and found moderate agreement between biological and clinical staging with either tracer. It is a diagnostic comparison study and does not test any treatment, cure, or prevention.

Study details

How this study scored 50/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 50 of 100.50 of 100 points earned50 not earned

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 446 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Tharick Ali Pascoal: h-index 61 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 10 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41452137)
Free to read 2 / 2 Free to read
Total 50 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Brain scans and imaging from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →